Neurobiology Research Unit and NeuroPharm, Rigshospitalet, Copenhagen, Denmark.
Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
J Psychopharmacol. 2022 Jan;36(1):74-84. doi: 10.1177/02698811211026454. Epub 2021 Jun 30.
Psilocybin is a psychedelic drug that has shown lasting positive effects on clinical symptoms and self-reported well-being following a single dose. There has been little research into the long-term effects of psilocybin on brain connectivity in humans.
Evaluate changes in resting-state functional connectivity (RSFC) at 1 week and 3 months after one psilocybin dose in 10 healthy psychedelic-naïve volunteers and explore associations between change in RSFC and related measures.
Participants received 0.2-0.3 mg/kg psilocybin in a controlled setting. Participants completed resting-state functional magnetic resonance imaging (fMRI) scans at baseline, 1-week and 3-month post-administration and [11C]Cimbi-36 PET scans at baseline and 1 week. We examined changes in within-network, between-network and region-to-region RSFC. We explored associations between changes in RSFC and psilocybin-induced phenomenology as well as changes in psychological measures and neocortex serotonin 2A receptor binding.
Psilocybin was well tolerated and produced positive changes in well-being. At 1 week only, executive control network (ECN) RSFC was significantly decreased (Cohen's = -1.73, pFWE = 0.010). We observed no other significant changes in RSFC at 1 week or 3 months, nor changes in region-to-region RSFC. Exploratory analyses indicated that decreased ECN RSFC at 1 week predicted increased mindfulness at 3 months ( = -0.65).
These findings in a small cohort indicate that psilocybin affects ECN function within the psychedelic 'afterglow' period. Our findings implicate ECN modulation as mediating psilocybin-induced, long-lasting increases in mindfulness. Although our findings implicate a neural pathway mediating lasting psilocybin effects, it is notable that changes in neuroimaging measures at 3 months, when personality changes are observed, remain to be identified.
裸盖菇素是一种迷幻药物,单次给药后,其对临床症状和自我报告的幸福感有持久的积极影响。关于裸盖菇素对人类大脑连接的长期影响,研究甚少。
评估 10 名健康的初次使用迷幻药物的志愿者单次使用裸盖菇素后 1 周和 3 个月的静息态功能连接(RSFC)变化,并探讨 RSFC 变化与相关测量指标之间的关联。
参与者在受控环境下接受 0.2-0.3mg/kg 的裸盖菇素。参与者在给药前、给药后 1 周和 3 个月完成静息态功能磁共振成像(fMRI)扫描,并在基线和给药后 1 周完成 [11C]Cimbi-36 PET 扫描。我们检查了内联网、外联网和区域间 RSFC 的变化。我们探讨了 RSFC 变化与裸盖菇素引起的现象学以及心理测量和新皮层 5-羟色胺 2A 受体结合变化之间的关联。
裸盖菇素耐受性良好,能显著改善幸福感。仅在 1 周时,执行控制网络(ECN)的 RSFC 显著降低(Cohen's d=-1.73,pFWE=0.010)。我们在 1 周或 3 个月时没有观察到其他 RSFC 的显著变化,也没有观察到区域间 RSFC 的变化。探索性分析表明,1 周时 ECN RSFC 的降低预测了 3 个月时正念的增加(r=-0.65)。
这些在小队列中的发现表明,裸盖菇素在迷幻“余辉”期间影响 ECN 功能。我们的研究结果表明,ECN 调节可能介导了裸盖菇素引起的、持久的正念增加。尽管我们的研究结果表明,神经影像学测量的变化在 3 个月时与人格变化有关,但仍需要确定。